ID

34563

Beskrivning

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).; ODM derived from: https://clinicaltrials.gov/show/NCT02480153

Länk

https://clinicaltrials.gov/show/NCT02480153

Nyckelord

  1. 2019-01-19 2019-01-19 -
Rättsinnehavare

see on clinicaltrials.gov

Uppladdad den

19 januari 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Rheumatoid Arthritis NCT02480153

Eligibility Rheumatoid Arthritis NCT02480153

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of rheumatoid arthritis based on 2010 acr/eular criteria for at least 4 months.
Beskrivning

ID.1

Datatyp

boolean

at least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.
Beskrivning

ID.2

Datatyp

boolean

hs-crp equal or greater than 8 mg/l.
Beskrivning

ID.3

Datatyp

boolean

must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose.
Beskrivning

ID.4

Datatyp

boolean

Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
evidence of untreated or inadequately treated latent or active tb.
Beskrivning

ID.5

Datatyp

boolean

evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (nyha class iii/iv) or malignancy in the previous 5 years.
Beskrivning

ID.6

Datatyp

boolean

history of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug.
Beskrivning

ID.7

Datatyp

boolean

may have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy).
Beskrivning

ID.8

Datatyp

boolean

any second dmard must be washed out prior to the first study dose.
Beskrivning

ID.9

Datatyp

boolean

Similar models

Eligibility Rheumatoid Arthritis NCT02480153

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
diagnosis of rheumatoid arthritis based on 2010 acr/eular criteria for at least 4 months.
boolean
ID.2
Item
at least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.
boolean
ID.3
Item
hs-crp equal or greater than 8 mg/l.
boolean
ID.4
Item
must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
evidence of untreated or inadequately treated latent or active tb.
boolean
ID.6
Item
evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (nyha class iii/iv) or malignancy in the previous 5 years.
boolean
ID.7
Item
history of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug.
boolean
ID.8
Item
may have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy).
boolean
ID.9
Item
any second dmard must be washed out prior to the first study dose.
boolean

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial